Resistance to keratolysis boosted by crosslinking

Article

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a recently published study.

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a study published in Cornea.

In a basic investigation, Barron artificial anterior chambers were used to perform ex vivo crosslinking of human corneas. The deepithelialized corneas were pretreated with riboflavin solution and irradiated with ultraviolet A (UVA) light for various durations. The corneas were then trephined and incubated with 0.3% collagenase A solution at 37 °C.

It was found that deepithelialized corneas that received no UV light and no riboflavin dissolved in 5.8 ± 0.6 hours. Increased resistance to dissolution was found in the crosslinked corneas, which demonstrated a time to dissolution of 17.8 ± 2.6 hours.

Longer UVA exposure increased the corneal tissues' resistance to collagenase, reaching a plateau at 30 minutes. Crosslinking the anterior corneas only provided the same amount of resistance as crosslinking both the anterior and posterior corneas.

Corneas that had been gamma-irradiated did not benefit from further crosslinking. They dissolved in 5.6 ± 1.2 hours when further crosslinked and 6.1 ± 0.6 hours when not.

To view an abstract of the study, click here.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.